Influence of ethnicity on response to asthma drugs

Cazzola, Mario; Rogliani, Paola; Sanduzzi, Alessandro; Matera, Maria Gabriella

doi:10.1517/17425255.2015.1047341

Cited by 16 publications

(4 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The "Asthma Inequality" is a well-known example showing the exacerbation in health disparity driven by missing minority subjects in research (Burchard, 2014;Cazzola et al, 2015). 21 Inhaled β2-agonists (such as Albuterol) are a widely used therapeutic drug for acute asthma.…”

Section: B Missing Diversity and Health Equity In The Era Of Genomic ...mentioning

confidence: 99%

NIH Grant Expansion, Ancestral Diversity and Scientific Discovery in Genomics Research

Fu¹,

Wang²

2022

View full text Add to dashboard Cite

We thank Feng Liu, Seth Richards-Shubik, Muzhe Yang and Fanny Leung for their valuable comments. All errors are our own. This study was supported by National Institute on Aging (U24AG041689, U54AG052427). The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

show abstract

Section: B Missing Diversity and Health Equity In The Era Of Genomic ...mentioning

confidence: 99%

NIH Grant Expansion, Ancestral Diversity and Scientific Discovery in Genomics Research

Fu¹,

Wang²

2022

View full text Add to dashboard Cite

show abstract

“…African‐American and Puerto Rican children also have a higher rate of asthma prevalence, mortality, and a lower drug response compared with Caucasians (Mak et al, ). This is of concern as, despite having more severe asthma, Puerto Rican children have a lower bronchodilator response to Albuterol, the most common drug prescribed for asthma exacerbations in children, compared with African‐American and Mexican children (Cazzola, Rogliani, Sanduzzi, & Matera, ). It is suggested that genetic variations contribute to the lower response to albuterol in Puerto Ricans and that genetics may also account for altered steroid responsiveness in African‐Americans with asthma (Cazzola et al, ).…”

Section: Vulnerability Factorsmentioning

confidence: 99%

“…This is of concern as, despite having more severe asthma, Puerto Rican children have a lower bronchodilator response to Albuterol, the most common drug prescribed for asthma exacerbations in children, compared with African‐American and Mexican children (Cazzola, Rogliani, Sanduzzi, & Matera, ). It is suggested that genetic variations contribute to the lower response to albuterol in Puerto Ricans and that genetics may also account for altered steroid responsiveness in African‐Americans with asthma (Cazzola et al, ). Researchers have also suggested that there is a variation in the PTCHD3 gene in African‐Americans that places them at a greater risk for developing asthma (White et al, ).…”

Section: Vulnerability Factorsmentioning

confidence: 99%

The modification of three vulnerability theories to assist nursing practice for school‐age children with severe asthma

Lack

Kinser

2019

Specialist Pediatric Nursing

View full text Add to dashboard Cite

Purpose Severe asthma is an inflammatory illness associated with adverse health outcomes and behaviors in children, such as decreased quality of life, impaired sleep, and increased medical costs and morbidity. Conclusions Children with severe asthma frequently exhibit a cycle of health and behaviors which contribute to these adverse health outcomes, consisting of decreased physical activity, increased stress, and increased airway inflammation and asthma exacerbations. School‐age children, in particular, are a vulnerable population because they not only rely on others for their care but also suffer from a chronic illness and are at risk for unequal healthcare access and health outcomes. Practice Implications Currently, there is no one nursing theory that adequately addresses the vulnerability, cycle of health and behaviors, and adverse health outcomes of children with severe asthma. By integrating key concepts from three vulnerability theories and presenting a modified conceptual framework, this paper aims to demonstrate how the use of this new conceptual framework may assist nurses in evaluating the unique needs of school‐age children with severe asthma to provide best practices and develop appropriate interventions.

show abstract

“…9 A 28-week safety extension of these studies (PINNACLE-3; NCT01970878) confirmed the long-term safety and efficacy of GFF MDI. 10 As patients of different ethnicities can respond differently to pharmacological therapies, 11,12 it is important to assess the efficacy and safety of new treatments in a range of patients from different geographical locations and ethnic backgrounds. The PINNACLE-4 study (NCT02343458) evaluated the efficacy and safety of GFF MDI in a geographically expanded population, which included patients from Asia, Europe, and the USA.…”

Section: Introductionmentioning

confidence: 99%

<p>Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD</p>

Chen

Zhong

Wang

et al. 2020

COPD

View full text Add to dashboard Cite

Background: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) is a long-acting muscarinic antagonist/long-acting β 2-agonist fixed-dose combination therapy delivered by MDI, formulated using innovative co-suspension delivery technology. The PINNACLE-4 study evaluated the efficacy and safety of GFF MDI in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) from Asia, Europe, and the USA. This article presents the results from the China subpopulation of PINNACLE-4. Methods: In this randomized, double-blind, placebo-controlled, parallel-group Phase III study (NCT02343458), patients received GFF MDI 18/9.6 µg, glycopyrrolate (GP) MDI 18 µg, formoterol fumarate (FF) MDI 9.6 µg, or placebo MDI (all twice daily) for 24 weeks. The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 second at Week 24. Secondary lung function endpoints and patient-reported outcome measures were also assessed. Safety was monitored throughout the study. Results: Overall, 466 patients from China were included in the intent-to-treat population (mean age 63.6 years, 95.7% male). Treatment with GFF MDI improved the primary endpoint compared to GP MDI, FF MDI, and placebo MDI (least squares mean differences: 98, 104, and 173 mL, respectively; all P≤0.0001). GFF MDI also improved daily total symptom scores and time to first clinically important deterioration versus monocomponents and placebo MDI, and Transition Dyspnea Index focal score versus placebo MDI. Rates of treatment-emergent adverse events were similar across the active treatment groups and slightly higher in the placebo MDI group. Conclusion: GFF MDI improved lung function and daily symptoms versus monocomponents and placebo MDI and improved dyspnea versus placebo MDI. All treatments were well tolerated with no unexpected safety findings. Efficacy and safety results were generally consistent with the global PINNACLE-4 population, supporting the use of GFF MDI in patients with COPD from China.

show abstract

Influence of ethnicity on response to asthma drugs

Cited by 16 publications

References 71 publications

NIH Grant Expansion, Ancestral Diversity and Scientific Discovery in Genomics Research

NIH Grant Expansion, Ancestral Diversity and Scientific Discovery in Genomics Research

The modification of three vulnerability theories to assist nursing practice for school‐age children with severe asthma

<p>Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD</p>

Contact Info

Product

Resources

About